Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1

Head and Neck Squamous Cell Carcinoma Clinical Trial

Official title:

A Prospective Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Combined With Anlotinib in First-line Treatment for Patients With of R/M HNSCC PD-L1 CPS≥1

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04999800
• Other study ID #: NCT20217
• Status: Recruiting
• Phase: Phase 2
• Start date: July 18, 2021
• Est. completion date: June 30, 2024

Study information

• Verified date: August 2021
• Source: Chinese Academy of Medical Sciences
• Contact: Yuankai Shi, MD
• Phone: +86-10-87788293
• Email: syuankaipumc[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is main evaluate the efficacy and safety of Pembrolizumab combined with Anlotinib in the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma with CPS≥1

Description:

This test is a single-center, prospective phase II clinical research, plan included in 20 cases of eligible subjects, assessment in China PD-L1 CPS≥1 or more recurrent and/or metastatic head and neck squamous cell carcinoma patients, Pembrolizumab combined with Anlotinib for the initial curative effect, adverse reaction and safety, provide the basis for subsequent clinical trials

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: June 30, 2024
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1) Voluntarily sign written informed consent before screening; 2) Age =18 years old; 3) ECOG physical status score 0-1; 4) Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (HNSCC) with primary site of oral cavity, oropharynx, hypopharynx or larynx; 5) Recurrent and/or metastatic HNSCC without indications of local radical treatment; 6) According to the efficacy evaluation criteria for solid tumors (RECIST version 1.1), at least one measurable lesion can be selected as the target lesion after receiving previous radiotherapy only if there has been definite disease progression 3 months after the end of radiotherapy; 7) Sufficient tumor tissue samples for PD-L1 immunohistochemical detection; 8) Expected survival of more than 3 months; 9) The main organs function normally, that is, they meet the following criteria: I. Blood routine (no blood transfusion, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment within 14 days before screening examination) : neutrophils =1.5× L09 /L, platelets =100×109/L, hemoglobin =90g/L; II. Liver function: ALT and AST, ALT and AST=3×ULN in patients without liver metastasis, ALT and AST=5×ULN in patients with liver metastasis;Total bilirubin (TBil) =1.5×ULN (Gilbert syndrome patients, =3 ×ULN); Iii. Renal function: Serum creatinine (CR) =1.5×ULN or creatinine clearance (CCR) =50ml/ min (subjects receiving carboplatin) or =60ml/ min (subjects receiving cisplatin); IV. Coagulation function: APTT, INR, PT =1.5×ULN; V. Echocardiography: left ventricular ejection fraction (LVEF) =50%; 10) Women should agree to use contraceptives (such as intrauterine devices [IUDs], contraceptives or condoms) during the study period and for 6 months after the end of the study;Negative blood pregnancy test within 7 days prior to study enrolment and must be non-lactating;Men should agree to use contraception during the study period and within 6 months after the end of the study period.

Exclusion Criteria:

• 1) The patient had necrotic lesions and was judged by the investigator to be at risk of massive bleeding; 2) A history of hypersensitivity to amlotinib or pabrizumab or any excipients; 3) Previous use of antiangiogenic drugs (such as amlotinib, apatinib, bevacizumab, Endox, etc.); 4) The patient is using (or cannot be discontinued within 1 week prior to the first dosing of the study treatment) a Chinese herbal medicine indicated for antitumor use; 5) poorly controlled pleural effusion, pericardial effusion or ascites requiring frequent drainage;Patients with indwelling catheters (such as the Pleurx ® catheter) are allowed to participate; 6) At the beginning of study treatment, there was still an uncured toxic reaction from previous treatment and CTCAE 5.0 was higher than level 1 (except for alopecia); 7) Spinal cord compression or symptomatic untreated brain or spinal cord metastases (except asymptomatic, stable condition, and no need for steroid therapy for 4 weeks prior to study treatment); 8) poorly controlled tumor-related pain.Patients who require analgesics must receive a steady dose before entering the study.Symptomatic lesions suitable for palliative radiotherapy (e.g., bone metastases or metastases leading to nerve damage) should be treated before enrolment.Prior to enrolment, local-regional treatment of asymptomatic metastatic lesions with further growth that may result in functional deficits or intractable pain (e.g., epidural metastases currently not associated with spinal cord compression) should be considered, if appropriate.

9) Hepatitis B, hepatitis C or human immunodeficiency virus (HIV antibody positive).Patients with positive hepatitis B antibodies were only eligible to participate in the study if they had HBV DNA ?2000cps/ml.Patients with hepatitis C antibody positive were eligible to participate in the study only if polymerase chain reaction showed HCV RNA negative; 10) Randomization of malignancies other than advanced head and neck squamous cell carcinoma with negligible risk of metastasis or death and expected radical outcome after treatment within the first 5 years (e.g.,Adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer for radical treatment, and ductal carcinoma in situ for radical surgery); 11) Had major surgery other than a diagnosis of advanced head and neck squamous cell carcinoma within 28 days prior to randomization or was expected to require major surgery during the study period; 12) patients who have had previous bone marrow transplantation or previous solid organ transplantation; 13) Any live vaccine (for example, vaccines against infectious diseases, such as influenza, varicella, etc.) was given within the first 4 weeks (28 days) of randomization; 14) any factors that may affect the patient's oral administration, such as inability to swallow, post-gastrointestinal resection, chronic diarrhea, and intestinal obstruction; 15) Meets any of the following cardiac criteria: mean corrected QT interval (QTc) from an electrocardiogram (ECG) in the resting state;470 msec (for the first anomaly, the test was retest once within 48 h, calculated based on the average result of two times).A variety of clinically significant cardiac rhythm, conduction, and resting ECG abnormalities, such as complete left bundle branch block, degree III, degree II, PR interval >250 msec.Various factors that may increase the risk of prolonged QTC or arrhythmic events, such as coronary heart disease, heart failure, hypokalemia, congenital long QT syndrome, a family history of first-degree relative with long QT syndrome or sudden unexplained death under age 40, and being on any known medication for prolonged QT; 16) Patients with any severe and/or uncontrolled disease, including but not limited to: patients with poor blood pressure control (systolic > 150 mmHg, diastolic > 100 mmHg);Suffer from myocardial ischemia or myocardial infarction, arrhythmias (including QTc =440ms) and congestive heart failure (New York Heart Association (NYHA) grade) of grade I or above;Active or uncontrolled severe infection (=CTC AE grade 2 infection);Cirrhosis, decompensated liver disease;Renal failure requires hemodialysis or peritoneal dialysis;Poor diabetes control (fasting blood glucose (FBG) > 10mmol/L);Routine urine indicated urinary protein =++, and confirmed 24-hour urinary protein quantitative > 1.0 g; 17) Patients with epileptic seizures requiring treatment, with a history of psychotropic substance abuse and unable to quit or with mental disorders; 18) Previous history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, and clinically evidenced active interstitial lung disease; 19) thrombotic or embolic venous or arterial events, such as cerebrovascular accidents, including transient ischemic attack, arterial thrombosis, deep vein thrombosis and pulmonary embolism, occurred within 6 months before enrollment;Has a history of hemorrhagic disease or abnormal blood clotting.

20) Lactating female patients.

Related Conditions & MeSH terms

• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Drug:
• Pembrolizumab
Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, an stomach cancer
• Anlotinib
Anlotinib is an oral small molecule multi-target receptor tyrosine kinase inhibitor

Locations

Country	Name	City	State
China	National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Shi Yuankai

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	tumor mutation burden(TMB)	Correlation results of tumor mutation burden(TMB)	3 year
Other	T cell gene expression	Correlation results of T cell gene expression	3 year
Primary	objective response rates(ORR)	To evaluate objective response rates of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) with PD-L1 CPS=1	1 year
Secondary	disease control rate(DCR)	To evaluate other efficacy indicators of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PD-L1 CPS=1, including disease control rate(DCR)	3 year
Secondary	duration of response(DOR)	To evaluate other efficacy indicators of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PD-L1 CPS=1, duration of response(DOR)	3 year
Secondary	progression-free survival(PFS)	To evaluate other efficacy indicators of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PD-L1 CPS=1, progression-free survival(PFS)	3 year
Secondary	overall survival (OS)	To evaluate other efficacy indicators of first-line Pembrolizumab combined with Anlotinib in Chinese patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PD-L1 CPS=1, overall survival (OS)	5 year